Profile data is unavailable for this security.
About the company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2022
- Employees3.00
- LocationCadrenal Therapeutics Inc822 A1a North, Suite 300PONTE VEDRA 32082United StatesUSA
- Phone+1 (904) 300-0701
- Fax+1 (302) 655-5049
- Websitehttps://www.cadrenal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 7.26m | 8.00 | -- | 2.63 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
| Trevena Inc | 3.14m | -40.15m | 7.34m | 23.00 | -- | -- | -- | 2.34 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Oragenics Inc | 20.63k | -20.26m | 7.35m | 5.00 | -- | 7.12 | -- | 356.20 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 7.36m | 1.00 | -- | 0.6841 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Scorpius Holdings Inc | 9.74m | -32.20m | 7.38m | 82.00 | -- | 0.0961 | -- | 0.757 | -1.22 | -1.40 | 0.3663 | 0.7937 | 0.1372 | -- | 26.56 | 118,815.70 | -47.81 | -39.37 | -58.20 | -43.18 | 68.56 | -- | -348.43 | -1,068.21 | 0.2641 | -198.18 | 0.3179 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
| Healthy Extracts Inc | 2.56m | -2.76m | 7.41m | -- | -- | 48.86 | -- | 2.89 | -0.9512 | -0.9512 | 0.8819 | 0.0512 | 0.9428 | 0.5035 | 32.10 | -- | -101.47 | -53.78 | -375.65 | -146.65 | 68.46 | 45.68 | -107.63 | -87.53 | 0.1293 | -2.22 | 0.879 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 7.50m | 4.00 | -- | 6.63 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| Twinlab Consolidated Holdings Inc | 12.65m | -9.55m | 7.51m | 17.00 | -- | -- | -- | 0.5941 | -0.0369 | -0.0502 | 0.0488 | -0.5447 | 1.01 | 1.49 | 7.30 | 743,941.20 | -76.13 | -60.53 | -- | -- | 34.59 | 21.36 | -75.51 | -37.72 | 0.0094 | -0.0108 | -- | -- | -20.87 | -28.58 | -20.28 | -- | -- | -- |
| Weed Inc | 0.00 | -5.19k | 7.62m | 2.00 | -- | 70.89 | 194.56 | -- | -0.00001 | -0.00001 | 0.00 | 0.0009 | 0.00 | -- | -- | 0.00 | -0.4942 | -385.93 | -9.56 | -822.37 | -- | -- | -- | -- | -- | -23.03 | 0.5461 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.69m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.72m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.78m | -2.66m | 7.81m | 30.00 | -- | 0.8357 | -- | 0.7989 | -0.14 | -0.14 | 0.651 | 0.5289 | 1.01 | 8.55 | 5.80 | -- | -27.53 | -3.83 | -33.16 | -5.02 | 13.56 | 14.55 | -27.25 | -3.04 | 3.98 | -162.45 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 7.95m | 10.00 | -- | 1.52 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -20.94m | 8.01m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 8.08m | -- | -- | -- | 5.33 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Cadrenal Therapeutics Inc's reporting currency: US Dollar USD
10.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 1.35m | 8.43% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 148.14k | 0.93% |
| Citadel Securities LLCas of 31 Mar 2024 | 55.85k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 42.87k | 0.27% |
| Virtu Americas LLCas of 31 Mar 2024 | 32.38k | 0.20% |
| Avantax Planning Partners, Inc.as of 31 Mar 2024 | 28.31k | 0.18% |
| XTX Markets LLCas of 31 Mar 2024 | 19.74k | 0.12% |
| Biltmore Family Office LLCas of 31 Mar 2024 | 11.00k | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 9.52k | 0.06% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
